Cargando…
Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311327/ https://www.ncbi.nlm.nih.gov/pubmed/34396043 http://dx.doi.org/10.1136/gpsych-2021-100561 |
| _version_ | 1783728937591898112 |
|---|---|
| author | Azfr Ali, Ruba Saleh Jalal, Zahraa Paudyal, Vibhu |
| author_facet | Azfr Ali, Ruba Saleh Jalal, Zahraa Paudyal, Vibhu |
| author_sort | Azfr Ali, Ruba Saleh |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8311327 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83113272021-08-12 Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? Azfr Ali, Ruba Saleh Jalal, Zahraa Paudyal, Vibhu Gen Psychiatr Commentary BMJ Publishing Group 2021-07-23 /pmc/articles/PMC8311327/ /pubmed/34396043 http://dx.doi.org/10.1136/gpsych-2021-100561 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Commentary Azfr Ali, Ruba Saleh Jalal, Zahraa Paudyal, Vibhu Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? |
| title | Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? |
| title_full | Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? |
| title_fullStr | Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? |
| title_full_unstemmed | Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? |
| title_short | Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? |
| title_sort | guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311327/ https://www.ncbi.nlm.nih.gov/pubmed/34396043 http://dx.doi.org/10.1136/gpsych-2021-100561 |
| work_keys_str_mv | AT azfralirubasaleh guidelinesversuspracticeinscreeningandmonitoringofcardiometabolicrisksinpatientstakingantipsychoticmedicationswheredowestand AT jalalzahraa guidelinesversuspracticeinscreeningandmonitoringofcardiometabolicrisksinpatientstakingantipsychoticmedicationswheredowestand AT paudyalvibhu guidelinesversuspracticeinscreeningandmonitoringofcardiometabolicrisksinpatientstakingantipsychoticmedicationswheredowestand |